Virax Biolabs Group Ltd
Company Profile
Business description
Virax Biolabs Group Ltd is a biotechnology company focused on the detection of immune responses and the development of immune profiling and in vitro diagnostic technologies for viral and immune-mediated diseases, with a current strategic focus on post-acute infection syndromes (PAIS) and related areas of chronic immune dysfunction. The company's principal development activities are centered on T cell-based in vitro diagnostics and immune profiling. The company's flagship product candidate, ViraxImmune, is an in-development T cell-based assay and immune profiling platform intended to support the assessment of immune dysfunction, initially in PAIS indications.
Contact
Bo’Ness Road Newhouse
BioCity Glasgow
Lanarkshire
MotherwellML1 5UH
GBRT: +44 2077887414
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2027
Employees
26
Stocks News & Analysis
stocks
Disney earnings: Experiences and streaming again drive excellent results
stocks
ASX utility share downgraded as electricity prices fall
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,450.90 | 39.60 | 0.42% |
| CAC 40 | 8,699.71 | 30.42 | 0.35% |
| DAX 40 | 26,140.13 | 13.83 | 0.05% |
| Dow JONES (US) | 53,885.10 | 464.02 | -0.85% |
| FTSE 100 | 10,867.89 | 20.41 | -0.19% |
| HKSE | 25,528.79 | 1.49 | -0.01% |
| NASDAQ | 26,348.35 | 15.09 | -0.06% |
| Nikkei 225 | 65,398.22 | 285.04 | -0.43% |
| NZX 50 Index | 13,824.13 | 133.93 | -0.96% |
| S&P 500 | 7,709.96 | 13.59 | -0.18% |
| S&P/ASX 200 | 9,269.10 | 40.30 | 0.44% |
| SSE Composite Index | 3,920.32 | 19.97 | 0.51% |